Updated Apr 19, 2021 03:54 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
B Value D Growth F Momentum C VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology and neuroscience markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining ...
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology and neuroscience markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva. Other relatively newer products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Kanjinti, Mvasi and Amgevita biosimilars.
Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. Biosimilar drugs are also a key part of Amgen’s growth strategy.
Epogen/Aranesp, Neupogen/Neulasta and Enbrel account for around half of Amgen’s revenues. While the erythropoiesis-stimulating agents (ESA) franchise consisting of Epogen and Aranesp contributed 9% to 2020 product sales, the granulocyte colony-stimulating factor (G-CSF) franchise comprising Neupogen/Neulasta contributed 10.1% to product sales in 2020. Enbrel accounted for 21% of product sales. Prolia/Xgeva sales in 2020 were $4.7 billion, accounting for almost 19% of product sales.
Amgen derives the bulk of its revenues from the domestic market (74.2% of total product sales in 2020). The company posted global sales of $24.2 billion in 2020, up 9% year over year.
ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA 91320
|Industry||Medical - Biomedical and Genetics|
|Fiscal Year End||December|
|Last Reported Quarter||3/31/2021|
|Next EPS Date||4/27/2021|
|Current Quarter EPS Consensus Estimate||4.03|
|Current Year EPS Consensus Estimate||16.72|
|Estimated Long-Term EPS Growth Rate||8.40|
|Next EPS Report Date||4/27/2021|
Price and Volume Information
|52 Week High||276.69|
|52 Week Low||210.28|
|20 Day Moving Average||2,084,893.38|
|Target Price Consensus||259.41|
|Trailing 12 Months||15.40|
|vs. Previous Year||4.67%|
|vs. Previous Quarter||-12.81%|
|vs. Previous Year||7.05%|
|vs. Previous Quarter||3.29%|
|Price / Sales||5.79|